Puma Biotechnology Inc. (NYSE: PBYI) reported mixed results for its
breast cancer treatment PB272 sending the stock price plummeting $39.05
to close at $170.67.
Puma Biotechnology reported mixed trial results
May 14, 2015 at 19:10 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.